Medindia LOGIN REGISTER
Medindia
Advertisement

Dr. Reddy's Laboratories Announces the Launch of Pregabalin Capsules in the U.S. Market

Wednesday, July 31, 2019 Drug News
Advertisement
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Pregabalin Capsules a therapeutic equivalent generic version of Lyrica® (pregabalin) Capsules approved by the U.S. Food and Drug Administration (USFDA).
Advertisement

The Lyrica® (pregabalin) Capsules brand had U.S. sales of approximately $5,462 million MAT for the most recent twelve months ending in May 2019 according to IQVIA Health*.
Advertisement

Dr. Reddy’s Pregabalin Capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg capsules in bottle count sizes of 90. This is also a controlled substance schedule V product.

Lyrica® is a trademark of C.P. PHARMACEUTICALS INTERNATIONAL C.V.

*IQVIA Retail and Non-Retail MAT May 2019.

RDY-0719-257

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation,

(i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events

(ii) mortality and morbidity levels and trends,

(iii) changing levels of competition and general competitive factors,

(iv) changes in laws and regulations and in the policies of central banks and/or governments,

(v) the impact of acquisitions or reorganization , including related integration issues. The company assumes no obligation to update any information contained herein.
Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close